Virtual ACC 2020 | More Evidence in Support of the Demanding 2017 Hypertension Guidelines

It’s been a while since the demanding and tough 2017 document written jointly between ACC and AHA where, with much controversy, cutoff hypertension values were taken to extreme limits. In fact, more flexible ESC guidelines came out a few months later.

Despite this document, hypertension-related cardiovascular death kept increasing in the US across all age subgroups and regions. 

Results from the present analysis are along the line of prior observational studies. The downward trend in cardiovascular mortality has been slowing down while death for cardiac failure has begun to climb. 

Data to be presented by Dr. Nambiar at the frustrated ACC 2020, to be published simultaneously in JACC, show death for hypertension adjusted by age every 100.000 persons has risen from 18.3 in 2007 to 23 in 2017 (p<0.001 for this trend).


Read also: Virtual ACC 2020 | Myocardial Ischemia Induced by Sudden Mental Stress.


During this same period, cardiovascular death related to hypertension increased 72% in rural US vs 20% in cities (p<0.001 for this trend).

Mortality has increased across all age groups, with the highest impact in people ranging from 65 to 74, for both sexes, but mostly for men.


Read also: Virtual ACC 2020 | “Dangerous” Plaques by CT Effectively Predict Infarction.


The reasons behind this increase are multiple, but clearly diabetes and hypertension epidemics weigh on.

Adjusting to the new cutoff values set in 2017 seems critical.

Original title: Decade long temporal trends in U.S. hypertension related cardiovascular mortality.

Reference: Nambiar L et al. J Am Coll Cardiol. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...